– USA, CA – Loyal, a biotech company developing the world’s first drugs intended to extend the healthy lifespan of dogs, today announced the appointment of Blake Scholl to its Board as an Independent Director, bringing over 20 years of successful startup, technical, and commercial experience to the Board.
“I’m extremely excited that Blake is joining Loyal’s Board. Blake is fascinated with longevity science, has a strong passion for tackling big, important problems, and has invaluable experience bringing entirely new products to consumers. I look forward to learning from and working with Blake,” said CEO and Founder, Celine Halioua.
About Blake Scholl
Blake Scholl is the Founder and CEO of Boom Supersonic, the company building the world’s fastest airliner. Boom has built XB-1, history’s first independently-developed supersonic jet, and taken orders and pre-orders for Overture, its supersonic passenger airliner. Before founding Boom in 2014, Blake held leadership roles at Amazon and Groupon and co-founded mobile technology startup Kima Labs.
Blake joins existing Board of Directors Laura Deming of The Longevity Fund, Celine Halioua, and Board Observers Josh Kopelman of First Round Capital and Greg Rosen of Box Group.
“Time is one of the most valuable commodities we have, which is why I’m inspired by Loyal’s mission to extend the time we have with our best friends, and increase their healthspan,” said Blake Scholl. “I’m excited to contribute my experience to their efforts.”
About Loyal
Loyal is a biotech startup developing the first drugs to help dogs live longer, healthier lives. By targeting and slowing the underlying ways dogs age, Loyal hopes to extend a healthy lifespan by reducing or delaying mortality due to age-associated diseases improving dogs’ quality of life, and extending their lifespan.
Loyal’s work is backed by decades of research and their team of experts in dog health and longevity is dedicated to expanding upon this research and developing better ways to quantify and improve the aging process in dogs.
The clinical-stage veterinary medicine company has two distinct products in its drug pipeline. The first aims to support healthy aging in older dogs of nearly every size and breed. The second hope is to address the longevity of large-breed dogs.
For more information: https://loyalfordogs.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
